From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety

Last Updated: Wednesday, September 20, 2023

Bispecific antibodies (BsAbs) represent a new treatment option for patients with multiple myeloma, even in high-risk and heavily pretreated patients. This review considers ways to improve the activity of these new BsAb therapies, as well as ways to reduce the risk of serious side effects, including cytokine release syndrome. 

Cancers (Basel)
Advertisement
News & Literature Highlights

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

Frontiers in Immunology

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

PharmacoEconomics

Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: A nationwide cohort study of patients with multiple myeloma in Finland

The Oncologist

Evaluating early intervention in smoldering myeloma clinical trials: A systematic review

NPJ Digital Medicine

Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma

Journal of Blood Medicine

Secondary polycythemia may be an early clinical manifestation of multiple myeloma: A case report

Advertisement
Advertisement